Pharsight

Zolpimist patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236285 AYTU Buccal, polar and non-polar spray containing zolpidem
Aug, 2032

(8 years from now)

Zolpimist is owned by Aytu.

Zolpimist contains Zolpidem Tartrate.

Zolpimist has a total of 1 drug patent out of which 0 drug patents have expired.

Zolpimist was authorised for market use on 19 December, 2008.

Zolpimist is available in spray, metered;oral dosage forms.

Zolpimist can be used as treatment of transient insomnia.

The generics of Zolpimist are possible to be released after 07 August, 2032.

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 19 December, 2008

Treatment: Treatment of transient insomnia

Dosage: SPRAY, METERED;ORAL

More Information on Dosage

ZOLPIMIST family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic